PharmaResearch Co., Ltd. (KOSDAQ:214450)
South Korea flag South Korea · Delayed Price · Currency is KRW
351,500
-14,500 (-3.96%)
Sep 10, 2026, 9:15 AM KST

PharmaResearch Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
185,690165,12192,04376,55140,57746,689
Depreciation & Amortization
16,80315,81513,64511,99610,6029,552
Loss (Gain) From Sale of Assets
-39.07162.1411.92-36.115,846-229.6
Asset Writedown & Restructuring Costs
2,2631,394-3,120-839.66
Loss (Gain) From Sale of Investments
-5,433-1,72920,191-3,0422,259-943.49
Loss (Gain) on Equity Investments
-414.54-425.47-5,954-680.032,192-556.93
Stock-Based Compensation
-149.42658.9657.1505.88-
Provision & Write-off of Bad Debts
273.91452.14-244.35582.21290.45-406.73
Other Operating Activities
25,35126,87917,3856,5127,5981,932
Change in Accounts Receivable
-13,425-4,445-8,535717.13-4,843-3,842
Change in Inventory
-37,030-26,249-11,940-28,188-8,3742,927
Change in Accounts Payable
236.26169.167,724-559.07597.78397.75
Change in Unearned Revenue
-288.26-7.9472.116.3211.36-
Change in Income Taxes
----9.631.52
Change in Other Net Operating Assets
-1,0955,87613,063-3,2302,1319,088
Operating Cash Flow
172,892183,162138,12264,94559,40465,297
Operating Cash Flow Growth
17.00%32.61%112.67%9.33%-9.03%101.59%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-34,996-29,727-36,415-12,063-17,257-20,645
Sale of Property, Plant & Equipment
70.63179.730.6828.65734.02-
Cash Acquisitions
-----35.01-
Sale (Purchase) of Intangibles
-1,650-4,877-2,310-623.05-460.83-2,786
Investment in Securities
-11,730-125,081-179,213-31,8605,446-66,427
Other Investing Activities
-1,238-82.432,507-522.63-794.6-590.91
Investing Cash Flow
-44,221-155,918-225,538-44,668-11,908-93,755

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
--10,782--50,000
Total Debt Issued
--10,782--50,000
Short-Term Debt Repaid
-----860-29.13
Long-Term Debt Repaid
--3,370-17,946-18,799-2,126-1,976
Total Debt Repaid
-5,829-3,370-17,946-18,799-2,986-2,005
Net Debt Issued (Repaid)
-5,829-3,370-7,164-18,799-2,98647,995
Issuance of Common Stock
---359.24--
Dividends Paid
-43,062-11,729-10,090-7,529-6,316-5,030
Other Financing Activities
-487.3-174-102.45-0--0
Financing Cash Flow
-49,378-15,273182,643-25,969-9,30142,965

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
5,207-1,6571,1184.41-76.12300.33
Miscellaneous Cash Flow Adjustments
-0-01,7580-6,862151.51
Net Cash Flow
84,50010,31598,103-5,68731,25714,959

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
137,896153,435101,70752,88342,14744,652
Free Cash Flow Growth
21.80%50.86%92.33%25.47%-5.61%-
Free Cash Flow Margin
22.85%28.61%29.05%20.26%21.64%28.98%
Free Cash Flow Per Share
11923.2513266.869879.605008.314224.854441.83
Levered Free Cash Flow
88,129109,27067,22521,15325,11527,225
Unlevered Free Cash Flow
94,606115,76570,12123,02027,50928,046

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
385.112,182428.67493.61159.45196.15
Cash Income Tax Paid
55,68839,61619,81116,96213,79810,051
Change in Working Capital
-51,602-24,657384.04-30,714-10,4678,421